Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK’s Promacta And Amgen’s Nplate To Face Off In ITP Market

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline’s thrombocytopenia treatment for patients with idiopathic thrombocytopenic purpura will launch the week of Nov. 24.

You may also be interested in...



GSK’s Promacta Adds ‘Breakthrough’ Claim On Strength Of Small NIH Study

Supplemental approval for severe aplastic anemia, a “breakthrough” designation, was based on a single-center, open-label Phase II trial in 43 patients that was conducted by the National Heart, Lung and Blood Institute.

GSK’s Promacta Cleared For Use With Interferon In Hep C Patients

The new indication fills an unmet need in a population of patients who have a short window to cure chronic hepatitis C infection before liver damage becomes too great for treatment, but for whom interferon-based therapy – currently their only option - is not indicated because of low platelet levels.

Amgen’s Nplate Has First Mandatory Patient Registration Under REMS

The Risk Evaluation and Mitigation Strategy for Amgen's platelet producer Nplate mandates enrollment at three levels of a controlled distribution system: institutions, physicians and patients

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel